Trending

24/7MN (NASDAQ: CYAD) Celyad Oncology shares are moving up in pre-market as news of the FDA lifting its clinical hold on upcoming phase 1b trial.

Shares are up 44% on 2.4 million in volume on more than 15,900 trades as of this post. The stock is $2.48 a share.

https://www.businesswire.com/news/home/20220731005044/en/Celyad-Oncology-Announces-FDA-Lifts-Clinical-Hold-of-CYAD-101-002-Phase-1b-Trial

RelatedNews

Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SIGN UP FOR OUR NEWSLETTER

Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist